SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing heightened volatility due to recent downgrades from Bank of America and Goldman Sachs, which many in the community are interpreting as manipulative tactics by competing institutions. Despite the short-term price pressure, a significant portion of investors remain highly bullish, viewing the dip as a prime buying opportunity ahead of upcoming earnings and potential S&P inclusion, confident in the company's long-term growth trajectory.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amidst its CES 2026 presence, where CEO Lisa Su unveiled new AI processors and a robust product roadmap, including the MI500 series aimed at significant AI performance gains. Despite an initial sell-off and community chatter about market manipulation, many are actively 'buying the dip,' bullish on AMD's aggressive product roadmap and long-term potential in the burgeoning AI and data center markets, challenging rivals like Nvidia.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant market momentum, primarily fueled by reports of persistent memory shortages and increasing demand for its storage solutions within the rapidly expanding AI infrastructure. This has created a highly polarized community discussion, with some investors celebrating its 'unstoppable' rise as a 'generational shift,' while others caution about an overextended 'bubble' and potential for sharp pullbacks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following its CES announcements, showcasing the Vera Rubin AI supercomputer and Alpamayo platform for autonomous vehicles. While enthusiasts celebrate these innovations as transformative for AI and robotics, many traders express frustration over the stock's struggle to sustain gains amid perceived market manipulation. The broader context reinforces NVIDIA's expanding role as a foundational technology provider in the evolving AI economy.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending after multiple analyst upgrades, with several firms designating it a "top pick" for 2026 and initiating or raising outlooks for a multi-year recovery. The community is actively discussing the stock's potential as a defensive play and a "safe haven" for capital, anticipating upward movement driven by strong fundamentals and upcoming financial reports.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is surging after announcing positive Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, showcasing strong skin clearance and a favorable safety profile that outperformed existing treatments. The community is buzzing with optimism about the drug's "best-in-class" potential and significant market opportunity, while others remain cautious, anticipating a potential secondary offering following the initial spike.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY Coin is currently trending with heightened trading volume, fueled by strong community anticipation for significant 2026 developments across decentralized AI, DePIN, and secure data monetization via its Layer-2 network. Supporters emphasize its foundational utility, regulatory compliance in Japan, and ex-Sony leadership as key strengths, though some investors remain cautious due to historical price volatility.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending following an agreement for Project TETRA, a DOE initiative to construct and operate a pilot reactor, which the community sees as a significant federal fast-track contract. Investors are actively comparing it to OKLO, highlighting its molten salt reactor technology and government backing as key differentiators for powering the growing demands of the AI revolution and industrial heat. Many view current levels as a long-term accumulation opportunity within the advanced nuclear sector.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

PMGC Holdings Inc. (ELAB) is experiencing extreme volatility following a recent reverse stock split that created an exceptionally low float, driving community speculation about a potential short squeeze due to high cost-to-borrow. This comes alongside news of a strategic acquisition in the micro modular reactor sector and advancements in an AI-driven drug discovery program, though many investors express strong skepticism, citing the company's history of dilution and repeated reverse splits.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is generating significant buzz following its recent substantial debt reduction and the strategic acquisition of Ask Sage, firmly positioning the company in secure generative AI for defense and government sectors. The community is actively discussing the imminent potential for major government contract wins, often drawing comparisons to early Palantir, despite some persistent chatter about potential share dilution. Many investors foresee a breakout into double-digit prices, driven by its strengthened financial position and perceived critical role in national security applications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Biotech Stocks To Keep An Eye On - December 9th

WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

<ul class="summary-bullets"><li>Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection.</li><li>Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection outcomes.</li><li>The treatment was well tolerated, with no burixafor-related side effects above Grade 2 reported in the study.</li></ul>Shares of Exicure Inc. (XCUR) surged nearly 40% on Tuesday after the company reported encouraging Phase 2 results for its experimental stem cell mobilization drug burixafor (GPC-100).&nbsp;The findings, shared at the American Society of Hematology meeting in Orlando, focused on patients with multiple myeloma preparing for autologous stem cell transplant.<h2 class="st-heading-2">Trial Meets Primary Endpoint</h2>The open-label, multicenter study found that 17 of 19 patients reached the trial’s stem cell collection target within two sessions. Two additional patients reached the target after an extra session.Among participants who proceeded to transplant, median neutrophil engraftment occurred in 13 days and platelet engraftment in 17.5 days. Exicure said burixafor worked quickly, boosting CD34+ stem cells, the cells doctors need to collect for transplant, within about an hour. The company said that the rapid rise makes it possible to give the drug and collect the cells on the same day.<h2 class="st-heading-2">Activity In Daratumumab-Exposed Patients</h2>Sixteen of 19 patients had previously received daratumumab, a therapy linked to reduced stem cell yield. Of these, 14 patients met the primary endpoint, including 12 of 14 who had also been treated with lenalidomide.Longer intervals between the last daratumumab dose and leukapheresis were associated with higher CD34+ cell yields.<h2 class="st-heading-2">Safety Findings</h2>The regimen of burixafor, propranolol, and G-CSF was well tolerated, with no adverse events above Grade 2 attributed to burixafor.“In this Phase 2 study, the combination of burixafor, G-CSF and propranolol showed an excellent safety profile and supported reliable mobilization of hematopoietic progenitor cells,” said lead investigator Jack Khouri of the Cleveland Clinic, adding that rapid cell mobilization may reduce the burden of the process for patients.<h2 class="st-heading-2">Pipeline Expansion Plans</h2>Burixafor, a selective CXCR4 antagonist acquired through Exicure’s January purchase of GPCR Therapeutics’ assets, is also being evaluated in sickle cell disease, rare transplant-eligible disorders, and cell and gene therapy settings.Exicure said a chemosensitization study in acute myeloid leukemia is planned, based on the drug’s ability to mobilize malignant cells from the bone marrow into peripheral blood.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Exicure was ‘extremely bullish’ amid ‘extremely high’ message volume. One user said, “Wow! This candle is showing a strong bullish setup. A powerful pump is coming.”<stembedurl>https://stocktwits.com/OmidArefi/message/638609203</stembedurl><figure class="image"><img style="aspect-ratio:968/141;" src="https://news.stocktwits-cdn.com/xcur_ss_png_95a0e0eba0.webp" alt="xcur ss.png" width="968" height="141"><figcaption>XCUR sentiment and message volume as of December 9| Source: Stocktwits</figcaption></figure>Another user called the stock cheap at the current price, “considering the data!”<stembedurl>https://stocktwits.com/Notoriousinvestor/message/638601332</stembedurl><a href="https://stocktwits.com/symbol/XCUR">Exicure’s stock</a> has declined 45% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exicure’s stock (XCUR) has declined 45% so far in 2025. (Photo credit: Getty Images)

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

Equity

Exicure, Inc. Loss At -$2.44 Mln In Q3

(RTTNews) - Exicure, Inc. (XCUR) reported Loss for third quarter of -$2.44 million...

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XCUR News

XCURExicure Inc